| Year |
Citation |
Score |
| 2023 |
Pierpont EI, Bennett AM, Schoyer L, Stronach B, Anschutz A, Borrie SC, Briggs B, Burkitt-Wright E, Castel P, Cirstea IC, Draaisma F, Ellis M, Fear VS, Frone MN, Flex E, ... ... Kontaridis MI, et al. The 8th International RASopathies Symposium: Expanding research and care practice through global collaboration and advocacy. American Journal of Medical Genetics. Part A. PMID 37969032 DOI: 10.1002/ajmg.a.63477 |
0.575 |
|
| 2022 |
Kontaridis MI, Chennappan S. Mitochondria and the future of RASopathies: the emergence of bioenergetics. The Journal of Clinical Investigation. 132: 1-5. PMID 35426371 DOI: 10.1172/JCI157560 |
0.354 |
|
| 2022 |
Kontaridis MI, Roberts AE, Schill L, Schoyer L, Stronach B, Andelfinger G, Aoki Y, Axelrad ME, Bakker A, Bennett AM, Broniscer A, Castel P, Chang CA, Cyganek L, Das TK, et al. The seventh international RASopathies symposium: Pathways to a cure-expanding knowledge, enhancing research, and therapeutic discovery. American Journal of Medical Genetics. Part A. PMID 35266292 DOI: 10.1002/ajmg.a.62716 |
0.606 |
|
| 2019 |
Gripp KW, Schill L, Schoyer L, Stronach B, Bennett AM, Blaser S, Brown A, Burdine R, Burkitt-Wright E, Castel P, Darilek S, Dias A, Dyer T, Ellis M, Erickson G, ... ... Kontaridis MI, et al. The sixth international RASopathies symposium: Precision medicine-From promise to practice. American Journal of Medical Genetics. Part A. PMID 31825160 DOI: 10.1002/Ajmg.A.61434 |
0.614 |
|
| 2019 |
Jaffré F, Miller CL, Schänzer A, Evans T, Roberts AE, Hahn A, Kontaridis MI. iPSC-Derived Cardiomyocytes Reveal Aberrant ERK5 and MEK1/2 Signaling Concomitantly Promote Hypertrophic Cardiomyopathy in RAF1-Associated Noonan Syndrome. Circulation. PMID 31163979 DOI: 10.1161/Circulationaha.118.037227 |
0.397 |
|
| 2019 |
Kaikkonen LA, Sätzler V, Roy A, Contreras M, Xu B, Stroll S, McCarthy J, Molkentin JD, Das S, Kontaridis M. Abstract 252: Activated Fibroblast-specific Deletion of RhoA Reduces Cardiac Fibrosis Through Regulation of the Non-canonical p38-MAPK Signaling Pathway Circulation Research. 125. DOI: 10.1161/Res.125.Suppl_1.252 |
0.489 |
|
| 2018 |
Li R, Baskfield A, Lin Y, Beers J, Zou J, Liu C, Jaffré F, Roberts AE, Ottinger EA, Kontaridis MI, Zheng W. Generation of an induced pluripotent stem cell line (TRNDi003-A) from a Noonan syndrome with multiple lentigines (NSML) patient carrying a p.Q510P mutation in the PTPN11 gene. Stem Cell Research. 34: 101374. PMID 30640061 DOI: 10.1016/J.Scr.2018.101374 |
0.334 |
|
| 2018 |
Zheng H, Yu WM, Waclaw RR, Kontaridis MI, Neel BG, Qu CK. Gain-of-function mutations in the gene encoding the tyrosine phosphatase SHP2 induce hydrocephalus in a catalytically dependent manner. Science Signaling. 11. PMID 29559584 DOI: 10.1126/Scisignal.Aao1591 |
0.442 |
|
| 2018 |
Sun C, Kontaridis MI. Physiology of Cardiac Development: From Genetics to Signaling to Therapeutic Strategies. Current Opinion in Physiology. 1: 123-139. PMID 29532042 DOI: 10.1016/J.Cophys.2017.09.002 |
0.35 |
|
| 2017 |
Wang J, Chandrasekhar V, Abbadessa G, Yu Y, Schwartz B, Kontaridis MI. In vivo efficacy of the AKT inhibitor ARQ 092 in Noonan Syndrome with multiple lentigines-associated hypertrophic cardiomyopathy. Plos One. 12: e0178905. PMID 28582432 DOI: 10.1371/Journal.Pone.0178905 |
0.362 |
|
| 2017 |
Simonson B, Subramanya V, Chan MC, Zhang A, Franchino H, Ottaviano F, Mishra MK, Knight AC, Hunt D, Ghiran I, Khurana TS, Kontaridis MI, Rosenzweig A, Das S. DDiT4L promotes autophagy and inhibits pathological cardiac hypertrophy in response to stress. Science Signaling. 10. PMID 28246202 DOI: 10.1126/Scisignal.Aaf5967 |
0.365 |
|
| 2016 |
Lauriol J, Cabrera JR, Roy A, Keith K, Hough SM, Damilano F, Wang B, Segarra GC, Flessa ME, Miller LE, Das S, Bronson R, Lee KH, Kontaridis MI. Developmental SHP2 dysfunction underlies cardiac hypertrophy in Noonan syndrome with multiple lentigines. The Journal of Clinical Investigation. PMID 27348588 DOI: 10.1172/Jci80396 |
0.396 |
|
| 2016 |
Wang J, Mizui M, Zeng LF, Bronson R, Finnell M, Terhorst C, Kyttaris VC, Tsokos GC, Zhang ZY, Kontaridis MI. Inhibition of SHP2 ameliorates the pathogenesis of systemic lupus erythematosus. The Journal of Clinical Investigation. PMID 27183387 DOI: 10.1172/Jci87037 |
0.38 |
|
| 2016 |
Breitkopf SB, Yang X, Begley MJ, Kulkarni M, Chiu YH, Turke AB, Lauriol J, Yuan M, Qi J, Engelman JA, Hong P, Kontaridis MI, Cantley LC, Perrimon N, Asara JM. A Cross-Species Study of PI3K Protein-Protein Interactions Reveals the Direct Interaction of P85 and SHP2. Scientific Reports. 6: 20471. PMID 26839216 DOI: 10.1038/Srep20471 |
0.432 |
|
| 2015 |
Korf B, Ahmadian R, Allanson J, Aoki Y, Bakker A, Wright EB, Denger B, Elgersma Y, Gelb BD, Gripp KW, Kerr B, Kontaridis M, Lazaro C, Linardic C, Lozano R, et al. The third international meeting on genetic disorders in the RAS/MAPK pathway: Towards a therapeutic approach. American Journal of Medical Genetics. Part A. PMID 25900621 DOI: 10.1002/Ajmg.A.37089 |
0.343 |
|
| 2015 |
Hahn A, Lauriol J, Thul J, Behnke-Hall K, Logeswaran T, Schänzer A, Bö?ürcü N, Garvalov BK, Zenker M, Gelb BD, von Gerlach S, Kandolf R, Kontaridis MI, Schranz D. Rapidly progressive hypertrophic cardiomyopathy in an infant with Noonan syndrome with multiple lentigines: palliative treatment with a rapamycin analog. American Journal of Medical Genetics. Part A. 167: 744-51. PMID 25708222 DOI: 10.1002/Ajmg.A.36982 |
0.361 |
|
| 2015 |
Lauriol J, Jaffré F, Kontaridis MI. The role of the protein tyrosine phosphatase SHP2 in cardiac development and disease. Seminars in Cell & Developmental Biology. 37: 73-81. PMID 25256404 DOI: 10.1016/J.Semcdb.2014.09.013 |
0.398 |
|
| 2014 |
Lauriol J, Keith K, Jaffré F, Couvillon A, Saci A, Goonasekera SA, McCarthy JR, Kessinger CW, Wang J, Ke Q, Kang PM, Molkentin JD, Carpenter C, Kontaridis MI. RhoA signaling in cardiomyocytes protects against stress-induced heart failure but facilitates cardiac fibrosis. Science Signaling. 7: ra100. PMID 25336613 DOI: 10.1126/Scisignal.2005262 |
0.376 |
|
| 2014 |
Paardekooper Overman J, Yi JS, Bonetti M, Soulsby M, Preisinger C, Stokes MP, Hui L, Silva JC, Overvoorde J, Giansanti P, Heck AJ, Kontaridis MI, den Hertog J, Bennett AM. PZR coordinates Shp2 Noonan and LEOPARD syndrome signaling in zebrafish and mice. Molecular and Cellular Biology. 34: 2874-89. PMID 24865967 DOI: 10.1128/Mcb.00135-14 |
0.657 |
|
| 2012 |
Dolmatova E, Spagnol G, Boassa D, Baum JR, Keith K, Ambrosi C, Kontaridis MI, Sorgen PL, Sosinsky GE, Duffy HS. Cardiomyocyte ATP release through pannexin 1 aids in early fibroblast activation. American Journal of Physiology. Heart and Circulatory Physiology. 303: H1208-18. PMID 22982782 DOI: 10.1152/Ajpheart.00251.2012 |
0.343 |
|
| 2011 |
Lauriol J, Kontaridis MI. PTPN11-associated mutations in the heart: has LEOPARD changed Its RASpots? Trends in Cardiovascular Medicine. 21: 97-104. PMID 22681964 DOI: 10.1016/J.Tcm.2012.03.006 |
0.398 |
|
| 2011 |
Marin TM, Keith K, Davies B, Conner DA, Guha P, Kalaitzidis D, Wu X, Lauriol J, Wang B, Bauer M, Bronson R, Franchini KG, Neel BG, Kontaridis MI. Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation. The Journal of Clinical Investigation. 121: 1026-43. PMID 21339643 DOI: 10.1172/Jci44972 |
0.444 |
|
| 2010 |
Stewart RA, Sanda T, Widlund HR, Zhu S, Swanson KD, Hurley AD, Bentires-Alj M, Fisher DE, Kontaridis MI, Look AT, Neel BG. Phosphatase-dependent and -independent functions of Shp2 in neural crest cells underlie LEOPARD syndrome pathogenesis. Developmental Cell. 18: 750-62. PMID 20493809 DOI: 10.1016/J.Devcel.2010.03.009 |
0.426 |
|
| 2008 |
Kontaridis MI, Yang W, Bence KK, Cullen D, Wang B, Bodyak N, Ke Q, Hinek A, Kang PM, Liao R, Neel BG. Deletion of Ptpn11 (Shp2) in cardiomyocytes causes dilated cardiomyopathy via effects on the extracellular signal-regulated kinase/mitogen-activated protein kinase and RhoA signaling pathways. Circulation. 117: 1423-35. PMID 18316486 DOI: 10.1161/Circulationaha.107.728865 |
0.498 |
|
| 2006 |
Bentires-Alj M, Kontaridis MI, Neel BG. Stops along the RAS pathway in human genetic disease Nature Medicine. 12: 283-285. PMID 16520774 DOI: 10.1038/Nm0306-283 |
0.378 |
|
| 2006 |
Kontaridis MI, Swanson KD, David FS, Barford D, Neel BG. PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects Journal of Biological Chemistry. 281: 6785-6792. PMID 16377799 DOI: 10.1074/Jbc.M513068200 |
0.386 |
|
| 2005 |
Haider UGB, Roos TU, Kontaridis MI, Neel BG, Sorescu D, Griendling KK, Vollmar AM, Dirsch VM. Resveratrol inhibits angiotensin II- and epidermal growth factor-mediated Akt activation: Role of Gab1 and Shp2 Molecular Pharmacology. 68: 41-48. PMID 15849355 DOI: 10.1124/Mol.104.005421 |
0.454 |
|
| 2004 |
Kontaridis MI, Eminaga S, Fornaro M, Zito CI, Sordella R, Settleman J, Bennett AM. SHP-2 positively regulates myogenesis by coupling to the Rho GTPase signaling pathway. Molecular and Cellular Biology. 24: 5340-52. PMID 15169898 DOI: 10.1128/Mcb.24.12.5340-5352.2004 |
0.54 |
|
| 2004 |
Ivins Zito C, Kontaridis MI, Fornaro M, Feng GS, Bennett AM. SHP-2 regulates the phosphatidylinositide 3'-kinase/Akt pathway and suppresses caspase 3-mediated apoptosis. Journal of Cellular Physiology. 199: 227-36. PMID 15040005 DOI: 10.1002/Jcp.10446 |
0.66 |
|
| 2004 |
Zhang SQ, Yang W, Kontaridis MI, Bivona TG, Wen G, Araki T, Luo J, Thompson JA, Schraven BL, Philips MR, Neel BG. Shp2 regulates SRC family kinase activity and Ras/Erk activation by controlling Csk recruitment. Molecular Cell. 13: 341-55. PMID 14967142 DOI: 10.1016/S1097-2765(04)00050-4 |
0.505 |
|
| 2002 |
Kontaridis MI, Liu X, Zhang L, Bennett AM. Role of SHP-2 in fibroblast growth factor receptor-mediated suppression of myogenesis in C2C12 myoblasts. Molecular and Cellular Biology. 22: 3875-91. PMID 11997521 DOI: 10.1128/Mcb.22.11.3875-3891.2002 |
0.694 |
|
| 2001 |
Kontaridis MI, Liu X, Zhang L, Bennett AM. SHP-2 complex formation with the SHP-2 substrate-1 during C2C12 myogenesis. Journal of Cell Science. 114: 2187-98. PMID 11493654 |
0.666 |
|
| Show low-probability matches. |